In this study we characterized the effects of the class I HDAC inhibitor nanatinostat and the pan-HDAC inhibitor panobinostat on four distinct EBV-positive lymphoblast cell lines: two related BL cell lines (Jijoye and its subclone, P3HR1 [40], modified to inducibly express BZLF1), an AIDS-associated immunoblastic lymphoma line (IBL-1), and a freshly-derived lymphoblastoid cell line (LCL), which models the precursor state of activated B cell diffuse large B cell lymphomas (ABC-DLBCL). The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.